IDX-899, an aryl phosphinate-indole non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection

Current Opinion in Investigational Drugs

Volumn 11, Issue 2, 2010, Pages 237-245

  Klibanov, Olga M ^a   Kaczor, Roberta L ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR PLUS RITONAVIR; DEXTROMETHORPHAN; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; FLURBIPROFEN; IDX 899; LOPINAVIR PLUS RITONAVIR; MIDAZOLAM; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ABNORMAL DREAMING; ANTIVIRAL ACTIVITY; ANXIETY; BACKACHE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DYSPEPSIA; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NAUSEA; NECK PAIN; OTALGIA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH INFECTION; TOOTH PAIN; VIVID DREAM; VOMITING;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INDOLES; PHOSPHINIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77649163883     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Non-nucleoside inhibitors of HIV-1 reverse transcriptase: Molecular modeling and X-ray structure investigations. Schafer W, Friebe W G, Leinert H, Mertens A, Poll T, Von der Saal W, Zilch H, Nuber B, Ziegler ML J MED CHEM 1993 36 726-732
2. Validation of a model for the complex of HIV-1 reverse transcriptase with non-nucleoside inhibitor TMC125. Udier Blagovic M, Tirado Rives J, Jorgensen WL J AM CHEM SOC 2003 125 20 6016-6017
3. IDX 12899: A novel and highly potent anti-HIV non-nucleosidic-reverse- transcriptase-inhibitor with enchanced barrier to resistance profle. Alexandre FR, Armador A, Bonaric S SCI-RSC MED CHEM SYMP 2007 14 September 24 Abs P21
4. IDX899 demonstrates rapid and profound inhibition of HIV replication in a phase I/II clinical trial in treatment-naive HIV-infected patients. Idenix Pharmaceuticals Inc PRESS RElEASE 2008 February 06
5. IDX12899 anti-HIV-1 activity and resistance profle is superior to efavirenz. Jakubik J, Seifer M, Gray L, Chapron C, Patty A, Dousson C, Standring DN ANTIVIR THER 2007 12 5 Abs 30
6. Tibotec conducts two pivotal phase III clinical trials studying TMC278 in treatment-naive adults with HIV. Tibotec Pharmaceuticals Ltd PRESS RElEASE 2008 July 17
7. In vitro cross-resistance profle, antiviral activity, safety and pharmacokinetics in HIV-1-infected patients of IDX899, a novel HIV-1 NNRTI with high barrier to resistance. Murphy R, Zala C, Jakubik JJ, Zhou XJ, Pietropaolo K, Chapron C, Hubbard L, Seifer M, Standring DN, Sullivan-Bolyai J, Belanger B et al ANTIVIR THER 2008 13 4 A7
8. In vitro cross-resistance profle for a next generation non-nucleoside reverse transcriptase inhibitor: IDX899. Jakubik JJ, Chapron C, Hubbard L, Seifer M, Standring DN ANTIVIR THER 2008 13 4 A28
9. Antiviral activity, safety and pharmacokinetics IDX899, a novel HIV-1 non-nucleoside reverse transcriptase inhibitor with high barrier to resistance, in treatment-naive HIV-1-infected patients. Murphy R, Zala C, Zhou XJ, Pictropaolo K, Sullivan-Bolyai J, Belanger B, Mayers D ANTIVIR THER 2008 13 4 A27
10. Optically pure synthesis of IDX899: An aryl phosphinate-indole (API) as novel NNRTI with potent anti-HIV activity and enhanced barrier to resistance. Alexandre FR, Amador A, Bonaric S et al AM CHEM SOC NATl MEET EXPOSITION 2008 236 August 20 Abs Medi-326
11. IDX899; a novel and highly potent anti-HIV non-nucleosidic-reverse- transcriptase inhibitor with enhanced barrier to resistance profle. Alexandre FR, Amador A, Bonaric S, Bot S, Caillet C, Convard T, Da Costa D, Dousson CB, Jacubik J, Liuzzi M, Parsy C et al AFMC INT MED CHEM SYMP 2008 20 September 01 Abs P001
12. HIV/AIDS surveillance report: Cases of HIV infection and AIDS in the United States and dependent areas, 2005. Centers for Disease Controls and Prevention COMPANY PUBlICATION 2007 17 June 28
13. Idenix Pharmaceuticals and GlaxoSmithKline sign worldwide license agreement for IDX899, a novel NNRTI for the treatment of HIV. Idenix Pharmaceuticals Inc PRESS RElEASE 2009 February 06
14. GlaxoSmithKline: Product development pipeline. GlaxoSmithKline plc COMPANY WORlD WIDE WEB SITE 2009 February 28
15. GlaxoSmithKline and Pfzer announce innovative agreement to create a new world-leading, specialist HIV company. GlaxoSmithKline plc; Pfzer Inc PRESS RElEASE 2009 April 16
16. GSK and Pfzer Innovative agreement creates specialist HIV company. GlaxoSmithKline plc; Pfzer Inc PRESS RElEASE 2009 April 16
17. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodefciency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects. Zhou XJ, Pietropaolo K, Damphousse D, Belanger B, Chen J, Sullivan-Bolyai J, Mayers D ANTIMICROB AGENTS CHEMOTHER 2009 53 5 1739-1746
18. ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care. ViiV Healthcare PRESS RELEASE 2009 November 03
19. Genotypic resistance and phenotypic cross-resistance profle in vitro for a novel NNRTI: IDX899. Richman D, Jakubik J, Chapron C, Hubbard L, Gray L, Seifer M, Standring D INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2008 15 Abs 729
20. Dose-escalation safety, tolerability, and pharmacokinetics of a novel HIV-1 NNRTI [IDX899] in healthy subjects. Mayers D, Hard M, Damphousse D, Fielman B, Sullivan-Bolyai J, Belanger B, Zhou XJ INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2008 15 Abs 764
21. IDX12899 and IDX12989, novel NNRTI with potent anti-HIV activity, enhanced barrier to resistance and favorable pharmacokinetic profle. Richman D, Dousson C, Storer R, Moussa A, Randall J, Bridges E, Liuzzi M, Jakubik J, Seifer M, Standring D INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2007 14 Abs 489
22. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects. Zhou XJ, Garner RC, Nicholson S, Kissling CJ, Mayers D J CLIN PHARMACOl 2009 49 12 1408-1416
23. IDX899 - A novel once-a-day second generation NNRTI for the treatment of HIV/AIDS. Mayers D, Murphy R, Zala C, Zhou XJ, Jakubik JJ, Pietropaolo K, Temam M-F, Belanger B, Sullivan-Bolyai J, Standring DN GAJ 2008 4 Suppl 1 Abs 43
24. Pharmacokinetic drug-drug interaction between IDX899 and atazanavir. Zhou XJ, Pietropaolo K, Belanger B, Damphousse D, Sullivan-Bolyai J, Mayers D INT AIDS CONF 2008 17 August 3-8 Abs TUPE0089
25. IDX899, a novel HIV-1 NNRTI with high barrier to resistance, provides suppression of HIV viral load in treatment-naive HIV-1-infected subjects. Zala C, Murphy R, Zhou XJ, Pietropaolo K, Sullivan-Bolyai J, Temam M-F, Belanger B, Mayers D INT AIDS CONF 2008 17 August 3-8 Abs THAB0402
26. Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. Borroto-Esoda K, Waters JM, Bae AS, Harris JL, Hinkle JE, Quinn JB, Rousseau FS AIDS RES HUM RETROVIRUSES 2007 23 8 988-995
27. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP et al J INFECT DIS 2008 197 6 867-870
28. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM, LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D et al J INFECT DIS 2004 189 12 2174-2180
29. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. Wensing AMJ, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I et al INFECT DIS 2005 192 6 958-966
30. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. Ross L, Lim ML, Liao QM, Wine B, Rodriguez AE, Weinberg W, Shaefer M HIV CLIN TRIAlS 2007 8 1 1-8
31. Time trends in primary resistance to HIV drugs in the United Kingdom: Multicentre observational study. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, Pillay D, Porter K, Pozniak A, Sabin C et al BR MED J 2005 331 7529 1368-1371
32. The prevalence of transmitted antiretroviral drug resistance in treatment-naive patients and factors infuencing frst-line treatment regimen selection. Huang HY, Daar ES, Sax PE, Young B, Cook P, Benson P, Cohen C, Scribner A, Hu H HIV MED 2008 9 5 285-293
33. Guidelines for the clinical management and treatment of HIV infected adults in Europe. European AIDS Clinical Society (EACS) EUR AIDS CLIN SOC 2009 October 22 3-23
34. Insights into DNA polymerization mechanisms from structure and function analysis of HIV-1 reverse transcriptase. Patel PH, Jacobo-Molina A, Ding J, Tantillo C, Clark AD, Raag R, Nanni RG, Hughes SH, Arnold E BIOCHEMISTRY 1995 34 16 5351-5363
35. Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants. Cancio R, Mai A, Rotili D, Artico M, Sbardella G, Clotet-Codina I, Este JA, Crespan E, Zanoli S, Hubscher U, Spadari S et al CHEMMEDCHEM 2007 2 4 445-448
36. Prescribing information: Intelence (Etravirine) tablets. Tibotec Inc DRUG PACKAGE INSERT 2008 January 18
37. Effcacy and safety of TMC-125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomized, double-blind, placebo-controlled trial. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trortier B, Peeters M, Vingerhoets J, de Smedt G et al LANCET 2007 370 9581 39-48
38. Effcacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: Primary 24-week analysis. Nadler JP AIDS 2007 21 6 F1-F10
39. Effcacy and safety of TMC-125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-Week results from a randomized, double-blind, placebo-controlled trial. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G et al LANCET 2007 370 9581 29-38
40. TMC278 (rilpivirine), a next-generation NNRTI, demonstrates long-term effcacy and tolerability in ARV-naive patients: 96-Week results of study C204. Santoscoy M, Cahn P, Gonsalez C, Hao W, Pozniak A, Shalit P, Vanveggel S, Boven K INT AIDS CONF 2008 17 Abs TUAB0103
41. Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor in treatment naive HIV patients. Moyle G, Boffto M, Manhard K, Sheedy B, Hingorani V, Yeh L-T, Quart B INT AIDS CONF 2008 17 Abs THAB0403
42. Short-term monotherapy with UK-453,061, a novel NNRTI, reduces viral load in HIV infected patients. Fatkenheuer G, Staszewski S, Plettenburg A, Hackman F, Layton G, McFadyen L, Davis J, Jenkins T INT AIDS SOC CONF HIV PATHOGENESIS TREAT 2007 4 Abs WESS202
43. Protocol summary for 113045: A phase I study to evaluate the effect of darunavir/ritonavir and lopinavir/ ritonavir on GSK2248761 pharmacokinetics and to assess the effect of GSK2248761 on CYP450 probe drugs in healthy adult subjects. GlaxoSmithKline plc COMPANY WORlD WIDE WEB SITE 2009 December 15
44. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Offce of AIDS Research Advisory Council (OARAC) INTERNET SITE 2009 December 01